Article
Public, Environmental & Occupational Health
Sharon J. Parish, James A. Simon, Susan R. Davis, Annamaria Giraldi, Irwin Goldstein, Sue W. Goldstein, Noel N. Kim, Sheryl A. Kingsberg, Abraham Morgentaler, Rossella E. Nappi, Kwangsung Park, Cynthia A. Stuenkel, Abdulmaged M. Traish, Linda Vignozzi
Summary: This study provides a clinical practice guideline for safely prescribing testosterone to women with HSDD, including identification of appropriate patients, dosing, and monitoring. Despite substantial evidence regarding safety, efficacy, and clinical use, access to testosterone therapy for the treatment of HSDD in women remains a significant unmet need.
JOURNAL OF WOMENS HEALTH
(2021)
Article
Health Care Sciences & Services
Guanjian Li, Weiran Li, Bing Song, Chao Wang, Qunshan Shen, Bo Li, Dongdong Tang, Chuan Xu, Hao Geng, Yang Gao, Guanxiong Wang, Huan Wu, Zhiguo Zhang, Xiaofeng Xu, Ping Zhou, Zhaolian Wei, Xiaojin He, Yunxia Cao
Summary: This study investigated the differences in gut microbiota and fecal metabolites between women with hypoactive sexual desire disorder (HSDD) and healthy controls, identifying significant disparities in microbial and metabolic signatures. These findings offer new insights for potentially influencing sexual desire by modifying gut microbiota.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2021)
Editorial Material
Obstetrics & Gynecology
Sharon J. Parish, Juliana M. Kling
Summary: Testosterone is an evidence-based therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Clinical practice guidelines state that HSDD in postmenopausal women is the only indication for testosterone therapy based on the most comprehensive meta-analysis to date. The guidelines also provide recommendations on patient identification, dosing, monitoring, and follow-up. This article discusses evidence-based testosterone therapy for management of HSDD in postmenopausal women.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
(2023)
Article
Medicine, General & Internal
Enav Friedmann, Julie Cwikel
Summary: This study explored the differences between men and women in their perceptions of the factors affecting women's sexual desire and the appropriate avenues for treatment. The results showed that women value interpersonal issues and physical attraction more, while men prioritize physical attraction and daily hassles as significant predictors of women's sexual desire. Additionally, women are more likely to endorse psychological help as a more appropriate treatment for HSDD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Obstetrics & Gynecology
Sheryl A. Kingsberg, Stephanie S. Faubion
Summary: This article discusses the high prevalence of hypoactive sexual desire disorder and its negative impact on women's health and quality of life. Despite healthcare professionals having the opportunity to address this issue, their limited awareness and comfort in dealing with sexual concerns often leads to patients remaining silent.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
(2022)
Review
Nursing
Jessica A. Pettigrew, Andrew M. Novick
Summary: Nearly half of women in the United States report sexual function problems, with many health care providers not asking about sexual concerns during routine clinical encounters due to various reasons. Hypoactive sexual desire disorder (HSDD) is the most commonly identified sexual problem among women, characterized by a deficiency of sexual thoughts, feelings, or receptiveness to sexual stimulation. Multiple hormones and neurotransmitters likely play a role in the physiology of HSDD, and validated screening tools are discussed for assessment and diagnosis.
JOURNAL OF MIDWIFERY & WOMENS HEALTH
(2021)
Article
Endocrinology & Metabolism
E. Maseroli, N. Verde, S. Cipriani, G. Rastrelli, C. Alfaroli, S. A. Ravelli, D. Costeniero, R. Scairati, M. Minnetti, F. Petraglia, R. S. Auriemma, R. E. Nappi, M. Maggi, L. Vignozzi
Summary: This study aimed to investigate the role of prolactin (PRL) in the female sexual response and found a correlation between high PRL levels and low desire, while among women with normal PRL levels, those with lower levels demonstrated poorer desire. The study also suggested that a PRL level of <9.83 μg/L could be used as a predictor for Hypoactive Sexual Desire Disorder (HSDD) and a lower sexual inhibitory trait.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2023)
Article
Psychology, Clinical
Glen I. Spielmans
Summary: The study found that bremelanotide had modest benefits for treating hypoactive sexual desire disorder (HSDD) in women, but participants significantly preferred placebo. Kingsberg et al.'s data reporting and measurement practices were incomplete and lacked transparency.
JOURNAL OF SEX RESEARCH
(2021)
Article
Chemistry, Medicinal
Guilherme Renke, Francisco Tostes
Summary: We discussed the CV safety and efficacy of subcutaneous testosterone therapy (STT) in postmenopausal women. Our proposed innovative criteria (IDEALSTT) for recommending STT include total testosterone level, carotid artery intima-media thickness, and calculated SCORE for 10-year CVD risk. While hormone replacement therapy (HRT) with testosterone has gained popularity in treating pre and postmenopausal women, the long-term safety and CV risk of STT in women are still controversial.
Review
Urology & Nephrology
Maria Uloko, Farah Rahman, Leah Ibrahim Puri, Rachel S. Rubin
Summary: As women age, there is a decrease in androgen production which can lead to Female Sexual Dysfunction (FSD) such as Hypoactive Sexual Desire Disorder (HSDD). Testosterone Replacement Therapy (TRT) is gaining interest as an effective treatment for postmenopausal women with HSDD, but more research is needed to understand its long-term effects in women of all ages.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
(2022)
Article
Public, Environmental & Occupational Health
Patricia Koochaki, Dennis Revicki, Hilary Wilson, Robin Pokrzywinski, Robert Jordan, Johna Lucas, Laura A. Williams, Amama Sadiq, Julie Krop
Summary: The study showed that bremelanotide significantly improves sexual desire and related distress in women with HSDD, enhancing the quality of sexual activities and communication in partner relationships. In comparison, the placebo mainly helps in seeking treatment actively and improving communication with partners without involving improvements in physiological responses.
JOURNAL OF WOMENS HEALTH
(2021)
Article
Public, Environmental & Occupational Health
James A. Simon, Amod Athavale, Rahul Ravindranath, Nandini Hadker, Amama Sadiq, Michelle Lim-Watson, Laura Williams, Julie Krop
Summary: Hypoactive sexual desire disorder (HSDD) has a negative impact on patients' mental health, especially among premenopausal women. However, this disorder is often neglected or left untreated.
JOURNAL OF WOMENS HEALTH
(2022)
Article
Urology & Nephrology
Charlene F. Belu, Serena Corsini-Munt, Justin P. Dube, Grace A. Wang, Natalie O. Rosen
Summary: This study found that partner responses to low desire in men with HSDD are associated with sexual satisfaction and distress for both members of the couple. When men perceived more facilitative partner responses, they and their partners reported greater sexual satisfaction. However, when men perceived more negative or avoidant partner responses, they and their partners reported lower sexual satisfaction. Additionally, when men perceived more avoidant partner responses, their partners reported greater sexual distress.
JOURNAL OF SEXUAL MEDICINE
(2023)
Article
Medicine, General & Internal
Theo Lerner, Vicente Renato Bagnoli, Elsa Aida Gay de Pereyra, Lucivanda Pontes Fonteles, Isabel Cristina Esposito Sorpreso, Jose Maria Soares Jr, Edmund Chada Baracat
Summary: Group CBT has been shown to be effective in treating Hypoactive Sexual Desire Disorder (HSDD), with significant improvement in sexual function observed in women undergoing therapy.
Article
Medicine, General & Internal
James A. Simon, Anita H. Clayton, Noel N. Kim, Sejal Patel
Summary: This study evaluated the clinically meaningful benefit of flibanserin in treating hypoactive sexual desire disorder (HSDD). The results showed that flibanserin treatment resulted in more patients reporting clinically meaningful benefit compared to placebo, with improvements in sexual desire, satisfying sexual events, and distress.
Editorial Material
Pharmacology & Pharmacy
Scott M. Berry
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2020)
Article
Multidisciplinary Sciences
Andrew Ip, Donald A. Berry, Eric Hansen, Andre H. Goy, Andrew L. Pecora, Brittany A. Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M. Berry, Nicholas S. Berry, Shivam Mathura, Ihor S. Sawczuk, Noa Biran, Ronaldo C. Go, Steven Sperber, Julia A. Piwoz, Bindu Balani, Cristina Cicogna, Rani Sebti, Jason Zuckerman, Keith M. Rose, Lisa Tank, Laurie Jacobs, Jason Korcak, Sarah L. Timmapuri, Joseph P. Underwood, Gregory Sugalski, Carol Barsky, Daniel W. Varga, Arif Asif, Joseph C. Landolfi, Stuart L. Goldberg
Article
Medicine, Research & Experimental
Brett L. Houston, Patrick R. Lawler, Ewan C. Goligher, Michael E. Farkouh, Charlotte Bradbury, Marc Carrier, Vlad Dzavik, Dean A. Fergusson, Robert A. Fowler, Jean-Phillippe Galanaud, Peter L. Gross, Emily G. McDonald, Mansoor Husain, Susan R. Kahn, Anand Kumar, John Marshall, Srinivas Murthy, Arthur S. Slutsky, Alexis F. Turgeon, Scott M. Berry, Robert S. Rosenson, Jorge Escobedo, Jose C. Nicolau, Lindsay Bond, Bridget-Anne Kirwan, Sophie de Brouwer, Ryan Zarychanski
Article
Medicine, General & Internal
Katherine Moll Reitz, Christopher W. Seymour, Jennifer Vates, Melanie Quintana, Kert Viele, Michelle Detry, Michael Morowitz, Alison Morris, Barbara Methe, Jason Kennedy, Brian Zuckerbraun, Timothy D. Girard, Oscar C. Marroquin, Stephen Esper, Jennifer Holder-Murray, Anne B. Newman, Scott Berry, Derek C. Angus, Matthew Neal
Article
Mathematical & Computational Biology
Stephen L. Lake, Melanie A. Quintana, Kristine Broglio, Jennifer Panagoulias, Scott M. Berry, Michael A. Panzara
Summary: A Bayesian adaptive design was proposed for a clinical trial in Duchenne muscular dystrophy, aiming to demonstrate treatment efficacy and identify early success on a biomarker. The trial incorporated placebo augmentation using data from past clinical trials and was selected for the US FDA Complex Innovative Trial Design Pilot Meeting Program, with the experience summarized.
STATISTICS IN MEDICINE
(2021)
Article
Genetics & Heredity
Nuria Carrillo, May C. Malicdan, Petcharat Leoyklang, Joseph A. Shrader, Galen Joe, Christina Slota, John Perreault, John D. Heiss, Bradley Class, Chia-Ying Liu, Kennan Bradley, Colleen Jodarski, Carla Ciccone, Claire Driscoll, Rebecca Parks, Scott Van Wart, Levent Bayman, Christopher S. Coffey, Melanie Quintana, Scott M. Berry, Marjan Huizing, William A. Gahl
Summary: This study evaluated the safety and efficacy of ManNAc in patients with GNE myopathy and found long-term safety, biochemical efficacy consistent with the intended mechanism of action, and preliminary evidence of clinical efficacy in patients.
GENETICS IN MEDICINE
(2021)
Article
Medicine, General & Internal
Ewan C. Goligher, Charlotte A. Bradbury, Bryan J. McVerry, Patrick R. Lawler, Jeffrey S. Berger, Michelle N. Gong, Marc Carrier, Harmony R. Reynolds, Anand Kumar, Alexis F. Turgeon, Lucy Z. Kornblith, Susan R. Kahn, John C. Marshall, Keri S. Kim, Brett L. Houston, Lennie P. G. Derde, Mary Cushman, Tobias Tritschler, Derek C. Angus, Lucas C. Godoy, Zoe McQuilten, Bridget-Anne Kirwan, Michael E. Farkouh, Maria M. Brooks, Roger J. Lewis, Lindsay R. Berry, Elizabeth Lorenzi, Anthony C. Gordon, Scott M. Berry, Colin J. McArthur, Matthew D. Neal, Judith S. Hochman, Steven A. Webb, Ryan Zarychanski, Tania Ahuja, Farah Al-Beidh, Djillali Annane, Yaseen M. Arabi, Diptesh Aryal, Lisa Baumann Kreuziger, Abi Beane, Zahra Bhimani, Shailesh Bihari, Henny H. Billett, Lindsay Bond, Marc Bonten, Frank Brunkhorst, Meredith Buxton, Adrian Buzgau, Lana A. Castellucci, Sweta Chekuri, Jen-Ting Chen, Allen C. Cheng, Tamta Chkhikvadze, Benjamin Coiffard, Aira Contreras, Todd W. Costantini, Sophie de Brouwer, Michelle A. Detry, Abhijit Duggal, Vladimir Dzavik, Mark B. Effron, Heather F. Eng, Jorge Escobedo, Lise J. Estcourt, Brendan M. Everett, Dean A. Fergusson, Mark Fitzgerald, Robert A. Fowler, Joshua D. Froess, Zhuxuan Fu, Jean P. Galanaud, Benjamin T. Galen, Sheetal Gandotra, Timothy D. Girard, Andrew L. Goodman, Herman Goossens, Cameron Green, Yonatan Y. Greenstein, Peter L. Gross, Rashan Haniffa, Sheila M. Hegde, Carolyn M. Hendrickson, Alisa M. Higgins, Alexander A. Hindenburg, Aluko A. Hope, James M. Horowitz, Christopher M. Horvat, David T. Huang, Kristin Hudock, Beverley J. Hunt, Mansoor Husain, Robert C. Hyzy, Jeffrey R. Jacobson, Devachandran Jayakumar, Norma M. Keller, Akram Khan, Yuri Kim, Andrei Kindzelski, Andrew J. King, Aaron E. Kornblith, Matthew E. Kutcher, Michael A. Laffan, Francois Lamontagne, Gregoire Le Gal, Christine M. Leeper, Eric S. Leifer, George Lim, Felipe Gallego Lima, Kelsey Linstrum, Edward Litton, Jose Lopez-Sendon, Sylvain A. Lother, Nicole Marten, Andrea Saud Marinez, Mary Martinez, Eduardo Mateos Garcia, Stavroula Mavromichalis, Daniel F. McAuley, Emily G. McDonald, Anna McGlothlin, Shay P. McGuinness, Saskia Middeldorp, Stephanie K. Montgomery, Paul R. Mouncey, Srinivas Murthy, Girish B. Nair, Rahul Nair, Alistair D. Nichol, Jose C. Nicolau, Brenda Nunez-Garcia, John J. Park, Pauline K. Park, Rachael L. Parke, Jane C. Parker, Sam Parnia, Jonathan D. Paul, Mauricio Pompilio, John G. Quigley, Robert S. Rosenson, Natalia S. Rost, Kathryn Rowan, Fernanda O. Santos, Marlene Santos, Mayler O. Santos, Lewis Satterwhite, Christina T. Saunders, Jake Schreiber, Roger E. G. Schutgens, Christopher W. Seymour, Deborah M. Siegal, Delcio G. Silva, Aneesh B. Singhal, Arthur S. Slutsky, Dayna Solvason, Anne M. Turner, Wilma Van Bentum-Puijk, Frank L. van de Veerdonk, Sean van Diepen, Gloria Vazquez-Grande, Lana Wahid, Vanessa Wareham, R. Jay Widmer, Jennifer G. Wilson, Eugene Yuriditsky, Yongqi Zhong
Summary: In critically ill patients with Covid-19, initial therapeutic-dose anticoagulation did not result in improved survival rates or fewer days requiring cardiovascular or respiratory organ support compared to usual-care pharmacologic thromboprophylaxis.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Donald A. Berry, Andrew Ip, Brett E. Lewis, Scott M. Berry, Nicholas S. Berry, Mary MrKulic, Virginia Gadalla, Burcu Sat, Kristen Wright, Michelle Serna, Rashmi Unawane, Katerina Trpeski, Michael Koropsak, Puneet Kaur, Zachary Sica, Andrew McConnell, Urszula Bednarz, Michael Marafelias, Andre H. Goy, Andrew L. Pecora, Ihor S. Sawczuk, Stuart L. Goldberg
Summary: A risk score utilizing six variables can predict mortality within 40 days of hospitalization for COVID-19 in patients within a hospital network in New Jersey, USA.
Review
Infectious Diseases
Cathrine Axfors, Perrine Janiaud, Andreas M. Schmitt, Janneke Van't Hooft, Emily R. Smith, Noah A. Haber, Akin Abayomi, Manal Abduljalil, Abdulkarim Abdulrahman, Yeny Acosta-Ampudia, Manuela Aguilar-Guisado, Farah Al-Beidh, Marissa M. Alejandria, Rachelle N. Alfonso, Mohammad Ali, Manaf AlQahtani, Alaa AlZamrooni, Juan-Manuel Anaya, Mark Angelo C. Ang, Ismael F. Aomar, Luis E. Argumanis, Alexander Averyanov, Vladimir P. Baklaushev, Olga Balionis, Thomas Benfield, Scott Berry, Nadia Birocco, Lynn B. Bonifacio, Asha C. Bowen, Abbie Bown, Carlos Cabello-Gutierrez, Bernardo Camacho, Adrian Camacho-Ortiz, Sally Campbell-Lee, Damon H. Cao, Ana Cardesa, Jose M. Carnate, German Jr J. Castillo, Rossana Cavallo, Fazle R. Chowdhury, Forhad U. H. Chowdhury, Giovannino Ciccone, Antonella Cingolani, Fresthel Monica M. Climacosa, Veerle Compernolle, Carlo Francisco N. Cortez, Abel Costa Neto, Sergio D'Antico, James Daly, Franca Danielle, Joshua S. Davis, Francesco Giuseppe De Rosa, Justin T. Denholm, Claudia M. Denkinger, Daniel Desmecht, Juan C. Diaz-Coronado, Juan A. Diaz Ponce-Medrano, Anne-Francoise Donneau, Teresita E. Dumagay, Susanna Dunachie, Cecile C. Dungog, Olufemi Erinoso, Ivy Mae S. Escasa, Lise J. Estcourt, Amy Evans, Agnes L. M. Evasan, Christian J. Fareli, Veronica Fernandez-Sanchez, Claudia Galassi, Juan E. Gallo, Patricia J. Garcia, Patricia L. Garcia, Jesus A. Garcia, Mutien Garigliany, Elvira Garza-Gonzalez, Deonne Thaddeus Gauiran, Paula A. Gaviria Garcia, Jose-Antonio Giron-Gonzalez, David Gomez-Almaguer, Anthony C. Gordon, Andre Gothot, Jeser Santiago Grass Guaqueta, Cameron Green, David Grimaldi, Naomi E. Hammond, Heli Harvala, Francisco M. Heralde, Jesica Herrick, Alisa M. Higgins, Thomas E. Hills, Jennifer Hines, Karin Holm, Ashraful Hoque, Eric Hoste, Jose M. Ignacio, Alexander Ivanov, Maike Janssen, Jeffrey H. Jennings, Vivekanand Jha, Ruby Anne N. King, Jens Kjeldsen-Kragh, Paul Klenerman, Aditya Kotecha, Fiorella Krapp, Luciana Labanca, Emma Laing, Mona Landin-Olsson, Pierre-Francois Laterre, Lyn-Li Lim, Jodor Lim, Oskar Ljungquist, Jorge M. Llaca-Diaz, Concepcion Lopez-Robles, Salvador Lopez-Cardenas, Ileana Lopez-Plaza, Josephine Anne C. Lucero, Maria Lundgren, Juan Macias, Sandy C. Maganito, Anna Flor G. Malundo, Ruben D. Manrique, Paola M. Manzini, Miguel Marcos, Ignacio Marquez, Francisco Javier Martinez-Marcos, Ana M. Mata, Colin J. McArthur, Zoe K. McQuilten, Bryan J. McVerry, David K. Menon, Geert Meyfroidt, Ma Angelina L. Mirasol, Benoit Misset, James S. Molton, Alric Mondragon, Diana M. Monsalve, Parastoo Moradi Choghakabodi, Susan C. Morpeth, Paul R. Mouncey, Michel Moutschen, Carsten Muller-Tidow, Erin Murphy, Tome Najdovski, Alistair D. Nichol, Henrik Nielsen, Richard M. Novak, Matthew V. N. O'Sullivan, Julian Olalla, Akin Osibogun, Bodunrin Osikomaiya, Salvador Oyonarte, Juan M. Pardo-Oviedo, Mahesh C. Patel, David L. Paterson, Carlos A. Pena-Perez, Angel A. Perez-Calatayud, Eduardo Perez-Alba, Anastasia Perkina, Naomi Perry, Mandana Pouladzadeh, Inmaculada Poyato, David J. Price, Anne Kristine H. Quero, Md M. Rahman, Md S. Rahman, Mayur Ramesh, Carolina Ramirez-Santana, Magnus Rasmussen, Megan A. Rees, Eduardo Rego, Jason A. Roberts, David J. Roberts, Yhojan Rodriguez, Jesus Rodriguez-Bano, Benjamin A. Rogers, Manuel Rojas, Alberto Romero, Kathryn M. Rowan, Fabio Saccona, Mehdi Safdarian, Maria Clariza M. Santos, Joe Sasadeusz, Gitana Scozzari, Manu Shankar-Hari, Gorav Sharma, Thomas Snelling, Alonso Soto, Pedrito Y. Tagayuna, Amy Tang, Geneva Tatem, Luciana Teofili, Steven Y. C. Tong, Alexis F. Turgeon, Januario D. Veloso, Balasubramanian Venkatesh, Yanet Ventura-Enriquez, Steve A. Webb, Lothar Wiese, Christian Wiken, Erica M. Wood, Gaukhar M. Yusubalieva, Kai Zacharowski, Ryan Zarychanski, Nina Khanna, David Moher, Steven N. Goodman, John P. A. Ioannidis, Lars G. Hemkens
Summary: This study assessed the benefits of convalescent plasma treatment compared to placebo or no treatment in COVID-19 patients and found that convalescent plasma treatment did not reduce all-cause mortality. The researchers recommend that convalescent plasma treatment for COVID-19 patients should not be used outside of randomized trials. Collaboration among trial investigators can inform both evidence generation and evidence application in patient care.
BMC INFECTIOUS DISEASES
(2021)
Article
Oncology
Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Harny, Marick Lae, Fabien Reyal, Gabes S. Sonke, Tessa G. Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martin, Maria del Monte-Millan, Sara Lopez-Tarruella, Judy C. Boughey, Matthew P. Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Stephen B. Edge, Jean E. Abraham, John M. S. Bartlett, Carlos Caldas, Janet Dunn, Helena Earl, Larry Hayward, Louise Hiller, Elena Provenzano, Stephen-John Sammut, Jeremy S. Thomas, David Cameron, Ashley Graham, Peter Hail, Lorna Mackintosh, Fang Fan, Andrew K. Godwin, Kelsey Schwensen, Priyanko Sharma, Angela M. DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J. van't Veer, Laura J. Esserman, W. Fraser Symmans
Summary: This study analyzed data from multiple independent cohorts to evaluate the relationship between residual cancer burden (RCB) and long-term prognosis in different subtypes of breast cancer. The results showed that higher RCB score was significantly associated with worse event-free survival in all breast cancer subtypes. The study suggests considering the evaluation of RCB as part of standard pathology reporting.
Article
Multidisciplinary Sciences
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Summary: HER2-targeted therapy significantly improves outcomes in early breast cancer patients. Two HER2-targeted combinations have shown promising efficacy in early breast cancer patients at high risk of recurrence, potentially aiding in identifying patients who can safely reduce cytotoxic chemotherapy without compromising outcomes.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. Van't Veer, Donald A. Berry, Laura J. Esserman
Summary: The study found that further development of anti-IGF-1R therapy will require better control of drug-induced hyperglycemia and the development of more predictive biomarkers.
Correction
Medicine, Research & Experimental
Pepa Bruce, Kate Ainscough, Lee Hatter, Irene Braithwaite, Lindsay R. Berry, Mark Fitzgerald, Thomas Hills, Kathy Brickell, David Cosgrave, Alex Semprini, Susan Morpeth, Scott Berry, Peter Doran, Paul Young, Richard Beasley, Alistair Nichol
Article
Medicine, Research & Experimental
Pepa Bruce Metadata, Kate Ainscough, Lee Hatter, Irene Braithwaite, Lindsay R. Berry, Mark Fitzgerald, Thomas Hills, Kathy Brickell, David Cosgrave, Alex Semprini, Susan Morpeth, Scott Berry, Peter Doran, Paul Young, Richard Beasley, Alistair Nichol
Summary: This article presents a practical model using Bayesian methods for rapid determination of the effectiveness of prophylactic agents in preventing COVID-19, but recruitment for the actual study did not start due to reduced COVID-19 cases in New Zealand and concerns about the efficacy and risks of HCQ treatment. The model can be easily adapted for other potential prophylactic agents and pathogens, and should be shared and incorporated into future pandemic preparedness planning.
Article
Medicine, Research & Experimental
Benjamin R. Saville, Donald A. Berry, Nicholas S. Berry, Kert Viele, Scott M. Berry
Summary: This study proposes a new analysis method, the Bayesian Time Machine, to address the issue of temporal drift in multi-arm platform trials. The results show that the Bayesian Time Machine provides better estimation of treatment effects and favorable testing properties compared to analyses using either concurrent or pooled controls.